Role of cytochrome P-450 as a source of catalytic iron in cisplatin- induced nephrotoxicity

Kidney International

Volumn 54, Issue 5, 1998, Pages 1562-1569

  Baliga, Radhakrishna ^b   Zhang, Zhiwei ^b   Baliga, Mithra ^b   Ueda, Norishi ^b   Shah, Sudhir V ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b NONE

Author keywords

Acute renal failure; Chemotherapeutic agent; Cimetidine; Free radical; LLC PK1 cells; Piperonyl butoxide; Tissue injury

Indexed keywords

BLEOMYCIN; CIMETIDINE; CISPLATIN; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; FREE RADICAL; HEMOPROTEIN; IRON; PIPERONYL BUTOXIDE;

ACUTE KIDNEY FAILURE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG INDUCED DISEASE; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE CELL; MALE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0031758531     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1998.00161.x     Document Type: Article

References (28)

1. HALLIWELL B, GUTTERIDGE JMC: Role of free radicals and catalytic metal ions in human disease. An overview. Method Enzymol 186:1-85, 1990
2. PALLER MS, HEDLUND BE: Role of iron in postischemic renal injury in the rat. Kidney Int 34:474-480, 1998
3. SHAH SV, WALKER PD: Evidence suggesting a role for hydroxyl radical in glycerol-induced acute renal failure. Am J Physiol 255:F438-F443, 1988
4. WALKER PD, SHAH SV: Evidence of the role of hydroxyl radical in gentamicin-induced acute renal failure in rats. J. Clin Invest 81:334-341, 1988
5. SHAH SV: Role of reactive oxygen metabolites in experimental glomerular disease. Kidney Int 35:1093-1106, 1989
6. 1 cells: A role for iron. Kidney Int 40:891-898, 1991
7. PALLER MS, NEUMANN TV: Reactive oxygen species and rat renal epithelial cells during hypoxia and reoxygenation. Kidney Int 40:1041-1049, 1991
8. BALIGA R, UEDA N, SHAH SV: Increase in bleomycin-detectable iron in ischaemia/reperfusion injury to rat kidneys. Biochem J 291:901-905, 1993
9. BALIGA R, ZHANG Z, BALIGA M, SHAH SV: Evidence for cytochrome P-450 as a source of catalytic iron in myoglobinuric acute renal failure. Kidney Int 49:362-369, 1996
10. BALIGA R, ZHANG Z, BALIGIA M, UEDA N, SHAH SV: In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity. Kidney Int 53:394-401, 1998
11. ROZENCWEIG M, VON HOFF DD, SLAVIK M, MUGGIA FM: Cisdiamminedichloroplatinum (II). A new anticancer drug. Ann Intern Med 86:803-812, 1977
12. BLACHLEY JD, HILL JB: Renal and electrolyte disturbances associated with cisplatin. Ann Intern Med 95:628-632, 1981
13. OZOLS RF, YOUNG RC: High-dose cisplatin therapy in ovarian cancer. Semin Oncol 12(Suppl 6):21-30, 1985
14. SAFIRSTEIN R, WINSTON J, MOEL D, DIKMAN S, GUTTENPLAN J: Cisplatin nephrotoxicity: Insights into mechanism. Int J Androl 10: 325-346, 1987
15. SUGIHARA K, GEMBA M: Modification of cisplatin toxicity by antioxidants. Jpn J Pharmacol 40:353-355, 1986
16. AGARWAL A, BALLA J, ALAM J, CROATT AJ, NATH K: Induction of heme oxygenase in toxic renal injury: A protective role in cisplatin nephrotoxicity in the rat. Kidney Int 48:1298-1307, 1995
17. BYSANI GK, KENNEDY TP, KY N, RAO NV, BLAZE CA, HOIDAL JR: Role of cytochrome P-450 in reperfusion injury of the rabbit lung. J Clin Invest 86:1434-1441, 1990
18. PALLER MS, JACOB HS: Cytochrome P-450 mediates tissue-damaging hydroxyl radical formation during reoxygenation of the kidney. Proc Natl Acad Sci USA 91:7002-7006, 1994
19. BOMPART G: Cisplatin-induced changes in cytochrome P-450, lipid peroxidation and drug-metabolizing enzyme activities in rat kidney cortex. Toxicol Lett 48:193-199, 1989
20. CAPASSO G, GIORDANO DR, DE TOMMASO G, DE SANTO NG, MASSRY SG: Parathyroidectomy has a beneficial effect on experimental cisplatin nephrotoxicity. Clin Nephrol 33:184-191, 1990
21. CUSHNER HM, BARNES JL, STEIN JH, REINFCK HJ: Role of volume depletion in the glycerol model of acute renal failure. Am J Physiol 250:F315-F321, 1986
22. ZAGER RA: Combined mannitol and deferoxamine therapy for myohemoglobinuric renal injury and oxidant tubular stress. Mechanistic and therapeutic implications. J Clin Invest 90:711-719, 1992
23. OMURA T, SATO R: The carbon monoxide-binding pigment of liver microsomes. I. Evidence of its hemoprotein nature. J Biol Chem 239:2370-2378, 1964
24. BALCERZAK M: Analytical methods for the determination of platinum in biological and enviromental materials. A review. Analyst 122:67R-74R, 1997
25. MAYS DC, HILLIARD JB, WONG DD, GERBER N: Activation of 8-methoxypsoralen by cytochrome P-450. Enzyme kinetics of covalent binding and influence of inhibitors and inducers of drug metabolism. Biochem Pharmacol 38:1647-1655, 1989
26. RENDIC S, KAJFEZ F, RUF HH: Characterization of cimetidine, ranitidine, and related structures' interaction with cytochrome P-450. Drug Metab Dispos 11:137-142, 1983
27. BAIRD MB, SFEIR GT, SLADE-PACINI CD: Lack of inhibition of mouse catalase activity by cimetidine: An argument against a relevant general effect of cimetidine upon heme metabolic pathways. Biochem Pharmacol 36:4366-4369, 1987
28. SLEIJFER DT, OFEERMAN JJG, MULDER NH, VERWEIJ M, VAN DER HEM GK, SCHRAFFORDT KOOPS H, MEIJER S: The protective potential of the combination of verapamil and cimetidine on cisplatin-induced nephrotoxicity in man. Cancer 60:2823-2828, 1987